20Med partners locally and globally with companies and other organisations to develop RNA and DNA vaccines and therapeutics.
20Med as a partner
The 20Med NP platform enables a broad range of potential applications, but every project has its unique set of challenges and requirements. Our team understands that it is of paramount importance to optimise each nanoparticle-payload combination specifically for the required target cells, to tissues with different phenotypes, and for different storage scenarios and routes of administration. By applying "science first" and data-driven approach, we aim to give each project the highest chances of success and accelerate projects towards clinical trials.
In February 2023, the Coalition for Epidemic Preparedness Innovations (CEPI), announced a partnership to advance the development of 20Med's bio-responsive Nanoparticle technology, which could help end the need for frozen storage of mRNA vaccines.
In April 2023, 20Med and Touchlight announced a collaboration to establish a novel vaccination platform that combines Touchlight's rapid enzymatic doggybone DNA with 20Med's bio-responsive Nanoparticle technology. Touchlight, as part of its funding from the Bill & Melinda Gates Foundation, will be able to further evaluate and determine the potential applicability of this technology combination.
20Med is open to discussing similar relationships with drug development companies and healthcare-focused organisations interested in PNP-based drug delivery.